Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 326

1.

PCASTt/SPCG-17-a randomised trial of active surveillance in prostate cancer: rationale and design.

Ahlberg MS, Adami HO, Beckmann K, Bertilsson H, Bratt O, Cahill D, Egevad L, Garmo H, Holmberg L, Johansson E, Rannikko A, Van Hemelrijck M, Jäderling F, Wassberg C, Åberg UWN, Bill-Axelson A.

BMJ Open. 2019 Aug 22;9(8):e027860. doi: 10.1136/bmjopen-2018-027860.

2.

The natural history of untreated muscle-invasive bladder cancer.

Martini A, Sfakianos JP, Renström-Koskela L, Mortezavi A, Falagario UG, Egevad L, Hosseini A, Mehrazin R, Galsky MD, Steineck G, Wiklund NP.

BJU Int. 2019 Jul 16. doi: 10.1111/bju.14872. [Epub ahead of print]

PMID:
31310696
3.

Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation.

Srigley JR, Delahunt B, Samaratunga H, Billis A, Cheng L, Clouston D, Evans A, Furusato B, Kench J, Leite K, MacLennan G, Moch H, Pan CC, Rioux-Leclercq N, Ro J, Shanks J, Shen S, Tsuzuki T, Varma M, Wheeler T, Yaxley J, Egevad L.

Pathology. 2019 Aug;51(5):463-473. doi: 10.1016/j.pathol.2019.05.001. Epub 2019 Jul 3. Review.

PMID:
31279442
4.

Is the UICC/AJCC pT2 Staging Category for Clear Cell Renal Cell Carcinoma Meaningful?

Delahunt B, Dagher J, Egevad L, Yaxley J, Varma M, Samaratunga H.

Am J Surg Pathol. 2019 Sep;43(9):1249-1252. doi: 10.1097/PAS.0000000000001308.

PMID:
31219816
5.

Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study.

Palsdottir T, Nordström T, Aly M, Lindberg J, Clements M, Egevad L, Grönberg H, Eklund M.

PLoS One. 2019 Jun 13;14(6):e0218280. doi: 10.1371/journal.pone.0218280. eCollection 2019.

6.

Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor.

Thysell E, Vidman L, Ylitalo EB, Jernberg E, Crnalic S, Iglesias-Gato D, Flores-Morales A, Stattin P, Egevad L, Widmark A, Rydén P, Bergh A, Wikström P.

Mol Oncol. 2019 Aug;13(8):1763-1777. doi: 10.1002/1878-0261.12526. Epub 2019 Jun 27.

7.

PD-L1 expression and deficient mismatch repair in ductal adenocarcinoma of the prostate.

Lindh C, Kis L, Delahunt B, Samaratunga H, Yaxley J, Wiklund NP, Clements M, Egevad L.

APMIS. 2019 Aug;127(8):554-560. doi: 10.1111/apm.12970.

PMID:
31127651
8.

Dataset for the reporting of prostate carcinoma in radical prostatectomy specimens: updated recommendations from the International Collaboration on Cancer Reporting.

Kench JG, Judge M, Delahunt B, Humphrey PA, Kristiansen G, Oxley J, Rasiah K, Takahashi H, Trpkov K, Varma M, Wheeler TM, Zhou M, Srigley JR, Egevad L.

Virchows Arch. 2019 Sep;475(3):263-277. doi: 10.1007/s00428-019-02574-0. Epub 2019 May 16. Review.

PMID:
31098802
9.

Percentage grade 4 tumour predicts outcome for clear cell renal cell carcinoma.

Dagher J, Delahunt B, Rioux-Leclercq N, Egevad L, Varma M, Samaratunga H.

Pathology. 2019 Jun;51(4):349-352. doi: 10.1016/j.pathol.2019.01.004. Epub 2019 Apr 12.

PMID:
30987774
10.

Immunoreactivity for prostate specific antigen and Ki67 differentiates subgroups of prostate cancer related to outcome.

Hammarsten P, Josefsson A, Thysell E, Lundholm M, Hägglöf C, Iglesias-Gato D, Flores-Morales A, Stattin P, Egevad L, Granfors T, Wikström P, Bergh A.

Mod Pathol. 2019 Sep;32(9):1310-1319. doi: 10.1038/s41379-019-0260-6. Epub 2019 Apr 12.

11.

Somatic alterations detected in diagnostic prostate biopsies provide an inadequate representation of multifocal prostate cancer.

Kristiansen A, Bergström R, Delahunt B, Samaratunga H, Guðjónsdóttir J, Grönberg H, Egevad L, Lindberg J.

Prostate. 2019 Jun;79(8):920-928. doi: 10.1002/pros.23797. Epub 2019 Mar 25.

PMID:
30908670
12.

Intraductal carcinoma of the prostate: a critical re-appraisal.

Varma M, Delahunt B, Egevad L, Samaratunga H, Kristiansen G.

Virchows Arch. 2019 May;474(5):525-534. doi: 10.1007/s00428-019-02544-6. Epub 2019 Mar 1. Review.

13.

The International Society of Urological Pathology Education web-a web-based system for training and testing of pathologists.

Egevad L, Delahunt B, Samaratunga H, Leite KR, Efremov G, Furusato B, Han M, Jufe L, Tsuzuki T, Wang Z, Hörnblad J, Clements M.

Virchows Arch. 2019 May;474(5):577-584. doi: 10.1007/s00428-019-02540-w. Epub 2019 Feb 21.

14.

Evolution, controversies and the future of prostate cancer grading.

Egevad L, Delahunt B, Yaxley J, Samaratunga H.

Pathol Int. 2019 Feb;69(2):55-66. doi: 10.1111/pin.12761. Epub 2019 Jan 29. Review.

PMID:
30694570
15.

Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with 68Ga-PSMA Positron Emission Tomography/Computerized Tomography Compared to Histological Correlation of Pelvic Lymph Node Pathology.

Yaxley JW, Raveenthiran S, Nouhaud FX, Samartunga H, Yaxley AJ, Coughlin G, Delahunt B, Egevad L, McEwan L, Wong D.

J Urol. 2019 Apr;201(4):815-820. doi: 10.1097/JU.0000000000000053.

PMID:
30672842
16.

Handling and reporting of pelvic lymphadenectomy specimens in prostate and bladder cancer: a web-based survey by the European Network of Uropathology.

Prendeville S, Berney DM, Bubendorf L, Compérat E, Egevad L, Hes O, Kristiansen G, Oxley J, van Leenders GJLH, Varma M, van der Kwast T.

Histopathology. 2019 May;74(6):844-852. doi: 10.1111/his.13818. Epub 2019 Apr 1.

PMID:
30604878
17.

Grading of renal cell carcinoma.

Delahunt B, Eble JN, Egevad L, Samaratunga H.

Histopathology. 2019 Jan;74(1):4-17. doi: 10.1111/his.13735. Review.

PMID:
30565310
18.

Prostate cancer induces C/EBPβ expression in surrounding epithelial cells which relates to tumor aggressiveness and patient outcome.

Adamo H, Hammarsten P, Hägglöf C, Dahl Scherdin T, Egevad L, Stattin P, Halin Bergström S, Bergh A.

Prostate. 2019 Apr;79(5):435-445. doi: 10.1002/pros.23749. Epub 2018 Dec 11.

PMID:
30536410
19.

The current status of renal cell carcinoma and prostate carcinoma grading.

Delahunt B, Egevad L, Yaxley J, Samaratunga H.

Int Braz J Urol. 2018 Nov-Dec;44(6):1057-1062. doi: 10.1590/S1677-5538.IBJU.2018.06.01. No abstract available.

20.

Dataset for the reporting of prostate carcinoma in core needle biopsy and transurethral resection and enucleation specimens: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Egevad L, Judge M, Delahunt B, Humphrey PA, Kristiansen G, Oxley J, Rasiah K, Takahashi H, Trpkov K, Varma M, Wheeler TM, Zhou M, Srigley JR, Kench JG.

Pathology. 2019 Jan;51(1):11-20. doi: 10.1016/j.pathol.2018.10.003. Epub 2018 Nov 23.

PMID:
30477882
21.

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis.

Mayrhofer M, De Laere B, Whitington T, Van Oyen P, Ghysel C, Ampe J, Ost P, Demey W, Hoekx L, Schrijvers D, Brouwers B, Lybaert W, Everaert E, De Maeseneer D, Strijbos M, Bols A, Fransis K, Oeyen S, van Dam PJ, Van den Eynden G, Rutten A, Aly M, Nordström T, Van Laere S, Rantalainen M, Rajan P, Egevad L, Ullén A, Yachnin J, Dirix L, Grönberg H, Lindberg J.

Genome Med. 2018 Nov 21;10(1):85. doi: 10.1186/s13073-018-0595-5.

22.

A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis.

Sjöberg E, Frödin M, Lövrot J, Mezheyeuski A, Johansson M, Harmenberg U, Egevad L, Sandström P, Östman A.

Br J Cancer. 2018 Oct;119(7):840-846. doi: 10.1038/s41416-018-0266-8. Epub 2018 Oct 8.

23.

Assessment of tumour-associated necrosis provides prognostic information additional to World Health Organization/International Society of Urological Pathology grading for clear cell renal cell carcinoma.

Dagher J, Delahunt B, Rioux-Leclercq N, Egevad L, Coughlin G, Dunglison N, Gianduzzo T, Kua B, Malone G, Martin B, Preston J, Pokorny M, Wood S, Samaratunga H.

Histopathology. 2019 Jan;74(2):284-290. doi: 10.1111/his.13737. Epub 2018 Oct 17.

PMID:
30129659
24.

Macroscopic features of prostate cancer.

Lindh C, Delahunt B, Egevad L.

Pathology. 2018 Jun;50(4):382-388. doi: 10.1016/j.pathol.2018.01.002. Epub 2018 Apr 27.

PMID:
29709289
25.

Re: Comment on Egevad et al., 'Utility of Pathology Imagebase for standardisation of prostate cancer grading'.

Egevad L, Samaratunga H, Delahunt B.

Histopathology. 2018 Aug;73(2):361-362. doi: 10.1111/his.13637. Epub 2018 May 30. No abstract available.

PMID:
29672898
26.

Intraoperative Consultation and Macroscopic Handling: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations.

Verrill C, Perry-Keene J, Srigley JR, Zhou M, Humphrey PA, Lopez-Beltran A, Egevad L, Ulbright TM, Tickoo SK, Epstein JI, Compérat E, Berney DM; Members of the ISUP Testicular Tumor Panel.

Am J Surg Pathol. 2018 Jun;42(6):e33-e43. doi: 10.1097/PAS.0000000000001049.

PMID:
29579010
27.

Utility of Pathology Imagebase for standardisation of prostate cancer grading.

Egevad L, Delahunt B, Berney DM, Bostwick DG, Cheville J, Comperat E, Evans AJ, Fine SW, Grignon DJ, Humphrey PA, Hörnblad J, Iczkowski KA, Kench JG, Kristiansen G, Leite KRM, Magi-Galluzzi C, McKenney JK, Oxley J, Pan CC, Samaratunga H, Srigley JR, Takahashi H, True LD, Tsuzuki T, van der Kwast T, Varma M, Zhou M, Clements M.

Histopathology. 2018 Jul;73(1):8-18. doi: 10.1111/his.13471. Epub 2018 Mar 5.

PMID:
29359484
28.

The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential.

Ström P, Nordström T, Aly M, Egevad L, Grönberg H, Eklund M.

Eur Urol. 2018 Aug;74(2):204-210. doi: 10.1016/j.eururo.2017.12.028. Epub 2018 Jan 10.

29.

Handling and reporting of transperineal template prostate biopsy in Europe: a web-based survey by the European Network of Uropathology (ENUP).

Kammerer-Jacquet SF, Compérat E, Egevad L, Hes O, Oxley J, Varma M, Kristiansen G, Berney DM.

Virchows Arch. 2018 Apr;472(4):599-604. doi: 10.1007/s00428-017-2265-1. Epub 2018 Jan 11.

PMID:
29327138
30.

Fuhrman grading is inappropriate for papillary renal cell carcinoma.

Delahunt B, Egevad L, Srigley JR, Samaratunga H.

World J Urol. 2018 Aug;36(8):1335-1336. doi: 10.1007/s00345-017-2153-y. Epub 2017 Dec 18. No abstract available.

PMID:
29256019
31.

Contemporary prognostic indicators for prostate cancer incorporating International Society of Urological Pathology recommendations.

Egevad L, Delahunt B, Kristiansen G, Samaratunga H, Varma M.

Pathology. 2018 Jan;50(1):60-73. doi: 10.1016/j.pathol.2017.09.008. Epub 2017 Dec 6. Review.

PMID:
29199015
32.

Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques.

Yaxley JW, Dagher J, Delahunt B, Egevad L, Srigley J, Samaratunga H.

World J Urol. 2018 Jan;36(1):15-20. doi: 10.1007/s00345-017-2119-0. Epub 2017 Nov 7.

PMID:
29116393
33.

Prognostic significance and biopsy characteristics of prostate cancer with seminal vesicle invasion on radical prostatectomy: a nationwide population-based study.

Kristiansen A, Drevin L, Delahunt B, Samaratunga H, Robinson D, Franck Lissbrant I, Stattin P, Egevad L.

Pathology. 2017 Dec;49(7):715-720. doi: 10.1016/j.pathol.2017.08.008. Epub 2017 Oct 14.

PMID:
29037803
34.

The decline of medical publishing: the rise of the pseudo-journal.

Delahunt B, Samaratunga H, Egevad L.

Pathology. 2017 Dec;49(7):673-674. doi: 10.1016/j.pathol.2017.08.001. Epub 2017 Sep 23. No abstract available.

PMID:
28950991
35.

Characterization of infiltrating lymphocytes in human benign and malignant prostate tissue.

Rådestad E, Egevad L, Jorns C, Mattsson J, Sundberg B, Nava S, Ericzon BG, Henningsohn L, Levitsky V, Uhlin M.

Oncotarget. 2017 Jul 24;8(36):60257-60269. doi: 10.18632/oncotarget.19528. eCollection 2017 Sep 1.

36.

Effect of Comorbidity on Prostate Cancer-Specific Mortality: A Prospective Observational Study.

Rajan P, Sooriakumaran P, Nyberg T, Akre O, Carlsson S, Egevad L, Steineck G, Wiklund NP.

J Clin Oncol. 2017 Nov 1;35(31):3566-3574. doi: 10.1200/JCO.2016.70.7794. Epub 2017 Sep 20.

37.

A novel technique for biobanking of large sections of radical prostatectomy specimens.

Lindh C, Delahunt B, Samaratunga H, Yaxley J, Gudjónsdóttir J, Clements M, Lindberg J, Egevad L.

Histopathology. 2018 Feb;72(3):481-489. doi: 10.1111/his.13386. Epub 2017 Nov 21.

PMID:
28881048
38.

Balancing Overdiagnosis and Early Detection of Prostate Cancer using the Stockholm-3 Model.

Nordström T, Grönberg H, Adolfsson J, Egevad L, Aly M, Eklund M.

Eur Urol Focus. 2018 Apr;4(3):385-387. doi: 10.1016/j.euf.2016.11.016. Epub 2016 Dec 19.

39.

The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50-69 yr Compared with Current Prostate Cancer Testing.

Eklund M, Nordström T, Aly M, Adolfsson J, Wiklund P, Brandberg Y, Thompson J, Wiklund F, Lindberg J, Presti JC, StLezin M, Clements M, Egevad L, Grönberg H.

Eur Urol Focus. 2018 Sep;4(5):707-710. doi: 10.1016/j.euf.2016.10.009. Epub 2016 Nov 23.

PMID:
28753803
40.

Oncologic Outcomes After Robot-assisted Radical Prostatectomy: A Large European Single-centre Cohort with Median 10-Year Follow-up.

Rajan P, Hagman A, Sooriakumaran P, Nyberg T, Wallerstedt A, Adding C, Akre O, Carlsson S, Hosseini A, Olsson M, Egevad L, Wiklund F, Steineck G, Wiklund NP.

Eur Urol Focus. 2018 Apr;4(3):351-359. doi: 10.1016/j.euf.2016.10.007. Epub 2016 Nov 2.

PMID:
28753802
41.

Pathology Imagebase-a reference image database for standardization of pathology.

Egevad L, Cheville J, Evans AJ, Hörnblad J, Kench JG, Kristiansen G, Leite KRM, Magi-Galluzzi C, Pan CC, Samaratunga H, Srigley JR, True L, Zhou M, Clements M, Delahunt B; ISUP Pathology Imagebase Expert Panel.

Histopathology. 2017 Nov;71(5):677-685. doi: 10.1111/his.13313. Epub 2017 Sep 13.

PMID:
28722802
42.

Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading.

Dagher J, Delahunt B, Rioux-Leclercq N, Egevad L, Srigley JR, Coughlin G, Dunglinson N, Gianduzzo T, Kua B, Malone G, Martin B, Preston J, Pokorny M, Wood S, Yaxley J, Samaratunga H.

Histopathology. 2017 Dec;71(6):918-925. doi: 10.1111/his.13311. Epub 2017 Oct 2.

PMID:
28718911
43.

Mucinous adenocarcinoma of prostate and prostatic adenocarcinoma with mucinous components: a clinicopathological analysis of 143 cases.

Samaratunga H, Delahunt B, Srigley JR, Yaxley J, Johannsen S, Coughlin G, Gianduzzo T, Kua B, Patterson I, Nacey JN, Egevad L.

Histopathology. 2017 Oct;71(4):641-647. doi: 10.1111/his.13278. Epub 2017 Jul 19.

PMID:
28590015
44.

Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death.

Cheteh EH, Augsten M, Rundqvist H, Bianchi J, Sarne V, Egevad L, Bykov VJ, Östman A, Wiman KG.

Cell Death Dis. 2017 Jun 1;8(6):e2848. doi: 10.1038/cddis.2017.225.

45.

Genetic profile of ductal adenocarcinoma of the prostate.

Seipel AH, Whitington T, Delahunt B, Samaratunga H, Mayrhofer M, Wiklund P, Grönberg H, Lindberg J, Egevad L.

Hum Pathol. 2017 Nov;69:1-7. doi: 10.1016/j.humpath.2017.04.015. Epub 2017 Apr 27.

PMID:
28457729
46.

Reporting and Staging of Testicular Germ Cell Tumors: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations.

Verrill C, Yilmaz A, Srigley JR, Amin MB, Compérat E, Egevad L, Ulbright TM, Tickoo SK, Berney DM, Epstein JI; Members of the International Society of Urological Pathology Testicular Tumor Panel.

Am J Surg Pathol. 2017 Jun;41(6):e22-e32. doi: 10.1097/PAS.0000000000000844.

PMID:
28368923
47.

Loss of chromosome Y leads to down regulation of KDM5D and KDM6C epigenetic modifiers in clear cell renal cell carcinoma.

Arseneault M, Monlong J, Vasudev NS, Laskar RS, Safisamghabadi M, Harnden P, Egevad L, Nourbehesht N, Panichnantakul P, Holcatova I, Brisuda A, Janout V, Kollarova H, Foretova L, Navratilova M, Mates D, Jinga V, Zaridze D, Mukeria A, Jandaghi P, Brennan P, Brazma A, Tost J, Scelo G, Banks RE, Lathrop M, Bourque G, Riazalhosseini Y.

Sci Rep. 2017 Mar 23;7:44876. doi: 10.1038/srep44876.

48.

Corrigendum to "Integration of Copy Number and Transcriptomics Provides Risk Stratification in Prostate Cancer: A Discovery and Validation Cohort Study" [EBioMedicine 2 (9) (2015) 1133-1144].

Ross-Adams H, Lamb AD, Dunning MJ, Halim S, Lindberg J, Massie CM, Egevad LA, Russell R, Ramos-Montoya A, Vowler SL, Sharma NL, Kay J, Whitaker H, Clark J, Hurst R, Gnanapragasam VJ, Shah NC, Warren AY, Cooper CS, Lynch AG, Stark R, Mills IG, Grönberg H, Neal DE; CamCaP Study Group.

EBioMedicine. 2017 Mar;17:238. doi: 10.1016/j.ebiom.2017.03.010. Epub 2017 Mar 8. No abstract available.

49.

UICC drops the ball in the 8th edition TNM staging of urological cancers.

Delahunt B, Egevad L, Samaratunga H, Varma M, Verrill C, Cheville J, Kristiansen G, Corbishley C, Berney DM.

Histopathology. 2017 Jul;71(1):5-11. doi: 10.1111/his.13200. No abstract available.

PMID:
28239904

Supplemental Content

Loading ...
Support Center